Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 113,084 shares at $14.00 ($1.6M) on 2014-10-22, disclosed to the SEC on 2014-10-24.
Scheduled sale ($1.6M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.00 | 109,534 | $1.5M | 96.7% |
| 2 | $14.24 | 1,700 | $24K | 1.5% |
| 3 | $15.19 | 1,850 | $28K | 1.8% |
| Total | $14.02 avg | 113,084 | $1.6M | 100% |
| Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |
| RGLS | SELL | 2014-10-03 | $69K | — | Filing → |